Dopamine in anorexia nervosa: A systematic review

Behavioural Pharmacology

Volumn 23, Issue 5-6, 2012, Pages 496-515

  Kontis, Dimitrios ^a   Theochari, E ^a  

^a Psychiatric Hospital of Attika Dafni   (Greece)

Author keywords

Anorexia nervosa; clinical; dopamine; preclinical; review

Indexed keywords

AMISULPRIDE; APOMORPHINE; ARIPIPRAZOLE; CATECHOL METHYLTRANSFERASE; CHLORPROMAZINE; CLOMIPRAMINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; FLUOXETINE; INSULIN; LEVODOPA; METOCLOPRAMIDE; MIRTAZAPINE; OLANZAPINE; PIMOZIDE; PROLACTIN; PROTIRELIN; QUETIAPINE; RISPERIDONE; SULPIRIDE;

ANIMAL MODEL; ANOREXIA NERVOSA; BODY WEIGHT; CALORIC INTAKE; CALORIC RESTRICTION; CEREBROSPINAL FLUID; CORPUS STRIATUM; DIET RESTRICTION; DNA METHYLATION; DNA POLYMORPHISM; DOPAMINE BLOOD LEVEL; DOPAMINE URINE LEVEL; DOUBLE BLIND PROCEDURE; FOOD INTAKE; GENETICS; HIPPOCAMPUS; HORMONAL REGULATION; HUMAN; HYPERACTIVITY; HYPOTHALAMUS; LOW DRUG DOSE; NEUROENDOCRINE SYSTEM; NEUROIMAGING; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ANIMALS; ANOREXIA NERVOSA; ANTIDEPRESSIVE AGENTS; CATECHOL O-METHYLTRANSFERASE; DEPRESSION; DOPAMINE; DOPAMINE ANTAGONISTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; NEUROENDOCRINE CELLS; ORGAN SPECIFICITY; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE D2; SYNAPTIC TRANSMISSION;

EID: 84864878382     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e328357e115     Document Type: Review

References (177)

1. Adams KL, Parfeniuk GG, Eikelboom R (2009). Chlorpromazine specifically prevents the wheel-induced feeding suppression in rats. Pharmacol Biochem Behav 93:470-473.
2. Aigner M, Treasure J, Kaye W, Kasper S (2011). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. World J Biol Psychiatry 12:400-443.
3. Alcaro A, Huber R, Panksepp J (2007). Behavioral functions of the mesolimbic dopaminergic system: an affective neuroethological perspective. Brain Res Rev 56:283-321.
4. American Psychiatric Association, Task Force on DSM-IV (2000). Diagnostic and statistical manual of mental disorders: DSM-IV-TR. Washington, DC: American Psychiatric Association.
5. Anderluh MB, Tchanturia K, Rabe-Hesketh S, Treasure J (2003). Childhood obsessive-compulsive personality traits in adult women with eating disorders: defining a broader eating disorder phenotype. Am J Psychiatry 160: 242-247.
6. Anstrom KK,Woodward DJ (2005). Restraint increases dopaminergic burst firing in awake rats. Neuropsychopharmacology 30:1832-1840.
7. Aragona M (2007). Tolerability and efficacy of aripiprazole in a case of psychotic anorexia nervosa comorbid with epilepsy and chronic renal failure. EatWeight Disord 12:e54-e57.
8. Attia E, Schroeder L (2005). Pharmacologic treatment of anorexia nervosa: where do we go from here? Int J Eat Disord 37 (Suppl):S60-S63, discussion S87-S69.
9. Attia E, Kaplan AS, Walsh BT, Gershkovich M, Yilmaz Z, Musante D, Wang Y (2011). Olanzapine versus placebo for out-patients with anorexia nervosa. Psychol Med 41:2177-2182.
10. Avena NM, Bocarsly ME (2012). Dysregulation of brain reward systems in eating disorders: neurochemical information from animal models of binge eating, bulimia nervosa, and anorexia nervosa. Neuropharmacology 63:87-96.
11. Avraham Y, Bonne O, Berry EM (1996). Behavioral and neurochemical alterations caused by diet restriction-the effect of tyrosine administration in mice. Brain Res 732:133-144.
12. Avraham Y, Saidian M, Burston JJ, Mevorach R, Vorobiev L, Magen I, et al. (2011). Fish oil promotes survival and protects against cognitive decline in severely undernourished mice by normalizing satiety signals. J Nutr Biochem 22:766-776.
13. Bachner-Melman R, Lerer E, Zohar AH, Kremer I, Elizur Y, Nemanov L, et al. (2007). Anorexia nervosa, perfectionism, and dopamine D4 receptor (DRD4). Am J Med Genet B Neuropsychiatr Genet 144B:748-756.
14. Baldo BA, Kelley AE (2007). Discrete neurochemical coding of distinguishable motivational processes: insights from nucleus accumbens control of feeding. Psychopharmacology (Berl) 191:439-459.
15. Baldo BA, Sadeghian K, Basso AM, Kelley AE (2002). Effects of selective dopamine D1 or D2 receptor blockade within nucleus accumbens subregions on ingestive behavior and associated motor activity. Behav Brain Res 137:165-177.
16. Barbarich NC, Kaye WH, Jimerson D (2003). Neurotransmitter and imaging studies in anorexia nervosa: new targets for treatment. Curr Drug Targets CNS Neurol Disord 2:61-72.
17. Barbarich NC, McConaha CW, Gaskill J, La Via M, Frank GK, Achenbach S, et al. (2004). An open trial of olanzapine in anorexia nervosa. J Clin Psychiatry 65:1480-1482.
18. Barbato G, Fichele M, Senatore I, Casiello M, Muscettola G (2006). Increased dopaminergic activity in restricting-type anorexia nervosa. Psychiatry Res 142:253-255.
19. Bardo MT, Donohew RL, Harrington NG (1996). Psychobiology of novelty seeking and drug seeking behavior. Behav Brain Res 77:23-43.
20. Barry VC, Klawans HL (1976). On the role of dopamine in the pathophysiology of anorexia nervosa. J Neural Transm 38:107-122.
21. Ben-Dor DH, Laufer N, Apter A, Frisch A, Weizman A (2002). Heritability, genetics and association findings in anorexia nervosa. Isr J Psychiatry Relat Sci 39:262-270.
22. Ben-Jonathan N, Hnasko R (2001). Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 22:724-763.
23. Bergen AW, Yeager M, Welch RA, Haque K, Ganjei JK, van den Bree MB, et al. (2005). Association of multiple DRD2 polymorphisms with anorexia nervosa. Neuropsychopharmacology 30:1703-1710.
24. Berridge KC (2007). The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology (Berl) 191:391-431.
25. Berridge KC, Robinson TE (1998). What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 28:309-369.
26. Berridge KC, Robinson TE (2003). Parsing reward. Trends Neurosci 26: 507-513.
27. Bissada H, Tasca GA, Barber AM, Bradwejn J (2008). Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 165:1281-1288.
28. Blackburn JR, Pfaus JG, Phillips AG (1992). Dopamine functions in appetitive and defensive behaviours. Prog Neurobiol 39:247-279.
29. Blinder BJ, Cumella EJ, Sanathara VA (2006). Psychiatric comorbidities of female inpatients with eating disorders. Psychosom Med 68:454-462.
30. Boachie A, Goldfield GS, Spettigue W (2003). Olanzapine use as an adjunctive treatment for hospitalized children with anorexia nervosa: case reports. Int J Eat Disord 33:98-103.
31. Bodell LP, Keel PK (2010). Current treatment for anorexia nervosa: efficacy, safety, and adherence. Psychol Res Behav Manag 3:91-108.
32. Bosanac P, Burrows G, Norman T (2003). Olanzapine in anorexia nervosa. Aust NZ J Psychiatry 37:494.
33. Bosanac P, Norman T, Burrows G, Beumont P (2005). Serotonergic and dopaminergic systems in anorexia nervosa: a role for atypical antipsychoticSAust NZ J Psychiatry 39:146-153.
34. Bosanac P, Kurlender S, Norman T, Hallam K, Wesnes K, Manktelow T, Burrows G (2007). An open-label study of quetiapine in anorexia nervosa. Hum Psychopharmacol 22:223-230.
35. Bowers MB Jr., Mazure CM, Greenfeld DG (1994). Elevated plasma monoamine metabolites in eating disorders. Psychiatry Res 52:11-15.
36. Brambilla F, Bellodi L, Arancio C, Ronchi P, Limonta D (2001). Central dopaminergic function in anorexia and bulimia nervosa: a psychoneuroendocrine approach. Psychoneuroendocrinology 26:393-409.
37. Brambilla F, Garcia CS, Fassino S, Daga GA, Favaro A, Santonastaso P, et al. (2007). Olanzapine therapy in anorexia nervosa: psychobiological effects. Int Clin Psychopharmacol 22:197-204.
38. Brambilla F, Dalle Grave R, Calugi S, Marchesini G, Baroni S, Marazziti D (2010). Effects of cognitive-behavioral therapy on eating disorders: neurotransmitter secretory response to treatment. Psychoneuroendocrinology 35: 729-737.
39. Brandys MK, Slof-Op't Landt MC, van Elburg AA, Ophoff R, Verduijn W, Meulenbelt I, et al. (2012). Anorexia nervosa and the Val158Met polymorphism of the COMT gene: meta-analysis and new data. Psychiatr Genet 22:130-136.
40. Brauer LH, De Wit H (1997). High dose pimozide does not block amphetamineinduced euphoria in normal volunteers. Pharmacol Biochem Behav 56: 265-272.
41. Brewerton TD, Hand LD, Bishop ER Jr (1993). The Tridimensional Personality Questionnaire in eating disorder patients. Int J Eat Disord 14:213-218.
42. Broocks A, Liu J, Pirke KM (1990). Semistarvation-induced hyperactivity compensates for decreased norepinephrine and dopamine turnover in the mediobasal hypothalamus of the rat. J Neural Transm Gen Sect 79: 113-124.
43. Bruins-Slot L, Gorwood P, Bouvard M, Blot P, Ades J, Feingold J, et al. (1998). Lack of association between anorexia nervosa and D3 dopamine receptor gene. Biol Psychiatry 43:76-78.
44. Cash TF, Deagle EA III (1997). The nature and extent of body-image disturbances in anorexia nervosa and bulimia nervosa: a meta-analysis. Int J Eat Disord 22:107-125.
45. Casper RC (2002). How useful are pharmacological treatments in eating disorderSPsychopharmacol Bull 36:88-104.
46. Casper RC (2006). The 'drive for activity' and 'restlessness' in anorexia nervosa: potential pathways. J Affect Disord 92:99-107.
47. Cassin SE, von Ranson KM (2005). Personality and eating disorders: a decade in review. Clin Psychol Rev 25:895-916.
48. Court A, Mulder C, Kerr M, Yuen HP, Boasman M, Goldstone S, et al. (2010). Investigating the effectiveness, safety and tolerability of quetiapine in the treatment of anorexia nervosa in young people: a pilot study. J Psychiatr Res 44:1027-1034.
49. Couturier J, Lock J (2007). A review of medication use for children and adolescents with eating disorders. J Can Acad Child Adolesc Psychiatry 16:173-176.
50. Dally P, Sargant W (1966). Treatment and outcome of anorexia nervosa. BMJ 2:793-795.
51. Dally PJ, Sargant W (1960). A new treatment of anorexia nervosa. BMJ 1: 1770-1773.
52. D'Andrea G, Ostuzzi R, Francesconi F, Musco F, Bolner A, d'Onofrio F, Colavito D (2009). Migraine prevalence in eating disorders and pathophysiological correlations. Neurol Sci 30 (Suppl 1):S55-S59.
53. Davis C, Woodside DB (2002). Sensitivity to the rewarding effects of food and exercise in the eating disorders. Compr Psychiatry 43:189-194.
54. Delgado MR, Jou RL, Phelps EA (2011). Neural systems underlying aversive conditioning in humans with primary and secondary reinforcers. Front Neurosci 5:71.
55. Dennis K, Le Grange D, Bremer J (2006). Olanzapine use in adolescent anorexia nervosa. Eat Weight Disord 11:e53-e56.
56. Diehl DJ, Gershon S (1992). The role of dopamine in mood disorders. Compr Psychiatry 33:115-120.
57. Dunican KC, DelDotto D (2007). The role of olanzapine in the treatment of anorexia nervosa. Ann Pharmacother 41:111-115.
58. Dunnett SB, Robbins TW (1992). The functional role of mesotelencephalic dopamine systems. Biol Rev Camb Philos Soc 67:491-518.
59. Ellinwood EH Jr., Sudilovsky A, Nelson LM (1973). Evolving behavior in the clinical and experimental amphetamine (model) psychosis. Am J Psychiatry 130:1088-1093.
60. Ercan ES, Copkunol H, Cykoethlu S, Varan A (2003). Olanzapine treatment of an adolescent girl with anorexia nervosa. Hum Psychopharmacol 18: 401-403.
61. Fairburn CG, Harrison PJ (2003). Eating disorders. Lancet 361:407-416.
62. Fisman S, Steele M, Short J, Byrne T, Lavallee C (1996). Case study: anorexia nervosa and autistic disorder in an adolescent girl. J Am Acad Child Adolesc Psychiatry 35:937-940.
63. Fladung AK, Gron G, Grammer K, Herrnberger B, Schilly E, Grasteit S, et al. (2010). A neural signature of anorexia nervosa in the ventral striatal reward system. Am J Psychiatry 167:206-212.
64. Frank GK, Bailer UF, Henry SE, Drevets W, Meltzer CC, Price JC, et al. (2005). Increased dopamine D2/D3 receptor binding after recovery from anorexia nervosa measured by positron emission tomography and [11c]raclopride. Biol Psychiatry 58:908-912.
65. Frank GK, Reynolds JR, Shott ME, Jappe L, Yang TT, Tregellas JR, O'Reilly RC (2012). Anorexia nervosa and obesity are associated with opposite brain reward response. Neuropsychopharmacology: 1-16.
66. Frieling H, Gozner A, Romer KD, Wilhelm J, Hillemacher T, Kornhuber J, et al. (2008). Alpha-synuclein mRNA levels correspond to beck depression inventory scores in females with eating disorders. Neuropsychobiology 58:48-52.
67. Frieling H, Romer KD, Scholz S, Mittelbach F, Wilhelm J, De Zwaan M, et al. (2010). Epigenetic dysregulation of dopaminergic genes in eating disorders. Int J Eat Disord 43:577-583.
68. Frisch A, Laufer N, Danziger Y, Michaelovsky E, Leor S, Carel C, et al. (2001). Association of anorexia nervosa with the high activity allele of the COMT gene: a family-based study in Israeli patients. Mol Psychiatry 6:243-245.
69. Frohman LA, Stachura ME (1975). Neuropharmacologic control of neuroendocrine function in man. Metabolism 24:211-234.
70. Gabrovsek M, Brecelj-Anderluh M, Bellodi L, Cellini E, Di Bella D, Estivill X, et al. (2004). Combined family trio and case-control analysis of the COMT Val158Met polymorphism in European patients with anorexia nervosa. Am J Med Genet B Neuropsychiatr Genet 124B:68-72.
71. Gawin F, Kleber H (1986). Pharmacologic treatments of cocaine abuse. Psychiatr Clin North Am 9:573-583.
72. Gelegen C, van den Heuvel J, Collier DA, Campbell IC, Oppelaar H, Hessel E, Kas MJ (2008). Dopaminergic and brain-derived neurotrophic factor signalling in inbred mice exposed to a restricted feeding schedule. Genes Brain Behav 7:552-559.
73. Gerner RH, Cohen DJ, Fairbanks L, Anderson GM, Young JG, Scheinin M, et al. (1984). CSF neurochemistry of women with anorexia nervosa and normal women. Am J Psychiatry 141:1441-1444.
74. Gillberg C (1983). Low dopamine and serotonin levels in anorexia nervosa. Am J Psychiatry 140:948-949.
75. Gillberg IC, Billstedt E, Wentz E, Anckarsater H, Rastam M, Gillberg C (2010). Attention, executive functions, and mentalizing in anorexia nervosa eighteen years after onset of eating disorder. J Clin Exp Neuropsychol 32:358-365.
76. Gillman MA, Lichtigfeld FJ (1986). The opioids, dopamine, cholecystokinin, and eating disorders. Clin Neuropharmacol 9:91-97.
77. Golden NH, Pepper GM, Sacker I, Avruskin TW (1992). The effects of a dopamine antagonist on luteinizing hormone and prolactin release in women with anorexia nervosa and in normal controls. J Adolesc Health 13:155-160.
78. Gorwood P, Bouvard M, Mouren-Simeoni MC, Kipman A, Ades J (1998). Genetics and anorexia nervosa: a review of candidate genes. Psychiatr Genet 8:1-12.
79. Grace AA (1991). Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41:1-24.
80. Gross HA, Lake CR, Ebert MH, Ziegler MG, Kopin IJ (1979). Catecholamine metabolism in primary anorexia nervosa. J Clin Endocrinol Metab 49: 805-809.
81. Hagman J, Gralla J, Sigel E, Ellert S, Dodge M, Gardner R, et al. (2011). A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study. J Am Acad Child Adolesc Psychiatry 50:915-924.
82. Halmi K, Sherman BS (1977). Dopaminergic and serotonergic regulation of growth hormone secretion in anorexia nervosa [proceedings]. Psychopharmacol Bull 13:63-65.
83. Haney M, Ward AS, Gerra G, Foltin RW (2001). Neuroendocrine effects of D-fenfluramine and bromocriptine following repeated smoked cocaine in humans. Drug Alcohol Depend 64:63-73.
84. Hao S, Avraham Y, Bonne O, Berry EM (2001). Separation-induced body weight loss, impairment in alternation behavior, and autonomic tone: effects of tyrosine. Pharmacol Biochem Behav 68:273-281.
85. Hay PJ, Claudino AM (2012). Clinical psychopharmacology of eating disorders: a research update. Int J Neuropsychopharmacol 15:209-222.
86. Hillebrand JJ, van Elburg AA, Kas MJ, van Engeland H, Adan RA (2005). Olanzapine reduces physical activity in rats exposed to activity-based anorexia: possible implications for treatment of anorexia nervosa? Biol Psychiatry 58:651-657.
87. Hinney A, Schneider J, Ziegler A, Lehmkuhl G, Poustka F, Schmidt MH, et al. (1999). No evidence for involvement of polymorphisms of the dopamine D4 receptor gene in anorexia nervosa, underweight, and obesity. Am J Med Genet 88:594-597.
88. Hoebel BG, Hernandez L, Schwartz DH, Mark GP, Hunter GA (1989). Microdialysis studies of brain norepinephrine, serotonin, and dopamine release during ingestive behavior. Theoretical and clinical implications. Ann NY Acad Sci 575:171-191; discussion 192-173.
89. Horvitz JC (2000). Mesolimbocortical and nigrostriatal dopamine responses to salient non-reward events. Neuroscience 96:651-656.
90. Jensen J, McIntosh AR, Crawley AP, Mikulis DJ, Remington G, Kapur S (2003). Direct activation of the ventral striatum in anticipation of aversive stimuli. Neuron 40:1251-1257.
91. Jensen VS, Mejlhede A (2000). Anorexia nervosa: treatment with olanzapine. Br J Psychiatry 177:87.
92. Johnson C, Stuckey M, Mitchell J (1983). Psychopharmacological treatment of anorexia nervosa and bulimia. Review and synthesis. J Nerv Ment Dis 171:524-534.
93. Johnston JL, Leiter LA, Burrow GN, Garfinkel PE, Anderson GH (1984). Excretion of urinary catecholamine metabolites in anorexia nervosa: effect of body composition and energy intake. Am J Clin Nutr 40: 1001-1006.
94. Joyce EM, Koob GF (1981). Amphetamine-, scopolamine-and caffeine-induced locomotor activity following 6-hydroxydopamine lesions of the mesolimbic dopamine system. Psychopharmacology (Berl) 73:311-313.
95. Judd SJ, Rakoff JS, Yen SS (1978). Inhibition of gonadotropin and prolactin release by dopamine: effect of endogenous estradiol levels. J Clin Endocrinol Metab 47:494-498.
96. Kafantaris V, Leigh E, Hertz S, Berest A, Schebendach J, Sterling WM (2011). A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa. J Child Adolesc Psychopharmacol 21:207-212.
97. Karwautz A, Rabe-Hesketh S, Hu X, Zhao J, Sham P, Collier DA, Treasure JL (2001). Individual-specific risk factors for anorexia nervosa: a pilot study using a discordant sister-pair design. Psychol Med 31:317-329.
98. Kaye W (2008). Neurobiology of anorexia and bulimia nervosa. Physiol Behav 94:121-135.
99. Kaye WH, Ebert MH, Raleigh M, Lake R (1984). Abnormalities in CNS monoamine metabolism in anorexia nervosa. Arch Gen Psychiatry 41: 350-355.
100. Kaye WH, Frank GK, McConaha C (1999). Altered dopamine activity after recovery from restricting-type anorexia nervosa. Neuropsychopharmacology 21:503-506.
101. Klump KL, Bulik CM, Pollice C, Halmi KA, Fichter MM, Berrettini WH, et al. (2000). Temperament and character in women with anorexia nervosa. J Nerv Ment Dis 188:559-567.
102. Kokkinidis L, Anisman H (1980). Amphetamine models of paranoid schizophrenia: an overview and elaboration of animal experimentation. Psychol Bull 88: 551-579.
103. Koob GF, Swerdlow NR (1988). The functional output of the mesolimbic dopamine system. Ann NY Acad Sci 537:216-227.
104. Krassas GE (2003). Endocrine abnormalities in Anorexia Nervosa. Pediatr Endocrinol Rev 1:46-54.
105. Kron L, Katz JL, Gorzynski G,Weiner H (1978). Hyperactivity in anorexia nervosa: a fundamental clinical feature. Compr Psychiatry 19:433-440.
106. Kruger S, Kennedy SH (2000). Psychopharmacotherapy of anorexia nervosa, bulimia nervosa and binge-eating disorder. J Psychiatry Neurosci 25: 497-508.
107. Kurup RK, Kurup PA (2003). Hypothalamic digoxin, hemispheric chemical dominance, and eating behavior. Int J Neurosci 113:1127-1141.
108. La Via MC, Gray N, Kaye WH (2000). Case reports of olanzapine treatment of anorexia nervosa. Int J Eat Disord 27:363-366.
109. Lawrence AD, Dowson J, Foxall GL, Summerfield R, Robbins TW, Sahakian BJ (2003). Impaired visual discrimination learning in anorexia nervosa. Appetite 40:85-89.
110. Lawson EA, Klibanski A (2008). Endocrine abnormalities in anorexia nervosa. Nat Clin Pract Endocrinol Metab 4:407-414.
111. Lechin F, van der Dijs B, Pardey-Maldonado B, Rivera JE, Baez S, Lechin ME (2010). Anorexia nervosa depends on adrenal sympathetic hyperactivity: opposite neuroautonomic profile of hyperinsulinism syndrome. Diabetes Metab Syndr Obes 3:311-317.
112. Lechin F, van der Dijs B, Pardey-Maldonado B, Baez S, Lechin ME (2011). Anorexia nervosa versus hyperinsulinism: therapeutic effects of neuropharmacological manipulation. Ther Clin Risk Manag 7:53-58.
113. Leggero C, Masi G, Brunori E, Calderoni S, Carissimo R, Maestro S, Muratori F (2010). Low-dose olanzapine monotherapy in girls with anorexia nervosa, restricting subtype: focus on hyperactivity. J Child Adolesc Psychopharmacol 20:127-133.
114. Levita L, Dalley JW, Robbins TW (2002). Nucleus accumbens dopamine and learned fear revisited: a review and some new findings. Behav Brain Res 137:115-127.
115. Lewis DA, Sesack SR (1997). Dopamine systems in the primate brain. In: Bloom EF, Bjorklund A, Hokfelt T, editors. The primate nervous system: part 1. Amsterdam: Elsevier. pp. 263-375.
116. Liggins J, Pihl RO, Benkelfat C, Leyton M (2012). The dopamine augmenter L-DOPA does not affect positive mood in healthy human volunteers. PLoS One 7:e28370.
117. Malina A, Gaskill J, McConaha C, Frank GK, LaVia M, Scholar L, Kaye WH (2003). Olanzapine treatment of anorexia nervosa: a retrospective study. Int J Eat Disord 33:234-237.
118. McKnight RF, Park RJ (2010). Atypical antipsychotics and anorexia nervosa: a review. Eur Eat Disord Rev 18:10-21.
119. Mehler C, Wewetzer C, Schulze U, Warnke A, Theisen F, Dittmann RW (2001). Olanzapine in children and adolescents with chronic anorexia nervosa. A study of five cases. Eur Child Adolesc Psychiatry 10:151-157.
120. Mehler-Wex C, Romanos M, Kirchheiner J, Schulze UM (2008). Atypical antipsychotics in severe anorexia nervosa in children and adolescents-review and case reports. Eur Eat Disord Rev 16:100-108.
121. Mendes MC, Ferriani RA, Costa LO, Moura MD, Silva de Sa MF (1995). Cortisol levels alter the response to metoclopramide in patients with hypothalamic amenorrhea. Gynecol Endocrinol 9:9-14.
122. Mikolajczyk E, Grzywacz A, Samochowiec J (2010). The association of catechol-O-methyltransferase genotype with the phenotype of women with eating disorders. Brain Res 1307:142-148.
123. Mitchell JE (1989). Psychopharmacology of eating disorders. Ann NY Acad Sci 575:41-48; discussion 49.
124. Mitchell JE, de Zwaan M, Roerig JL (2003). Drug therapy for patients with eating disorders. Curr Drug Targets CNS Neurol Disord 2:17-29.
125. Mondraty N, Birmingham CL, Touyz S, Sundakov V, Chapman L, Beumont P (2005). Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa. Australas Psychiatry 13:72-75.
126. Moore RY, Bloom FE (1978). Central catecholamine neuron systems: anatomy and physiology of the dopamine systems. Annu Rev Neurosci 1:129-169.
127. Nann-Vernotica E, Donny EC, Bigelow GE, Walsh SL (2001). Repeated administration of the D1/5 antagonist ecopipam fails to attenuate the subjective effects of cocaine. Psychopharmacology (Berl) 155:338-347.
128. Newman-Toker J (2000). Risperidone in anorexia nervosa. J Am Acad Child Adolesc Psychiatry 39:941-942.
129. Nisoli E, Brunani A, Borgomainerio E, Tonello C, Dioni L, Briscini L, et al. (2007). D2 dopamine receptor (DRD2) gene Taq1A polymorphism and the eatingrelated psychological traits in eating disorders (anorexia nervosa and bulimia) and obesity. Eat Weight Disord 12:91-96.
130. Norris ML, Spettigue W, Buchholz A, Henderson KA, Gomez R, Maras D, et al. (2011). Olanzapine use for the adjunctive treatment of adolescents with anorexia nervosa. J Child Adolesc Psychopharmacol 21:213-220.
131. Nudel DB, Gootman N, Nussbaum MP, Shenker IR (1984). Altered exercise performance and abnormal sympathetic responses to exercise in patients with anorexia nervosa. J Pediatr 105:34-37.
132. Owesson-White CA, Roitman MF, Sombers LA, Belle AM, Keithley RB, Peele JL, et al. (2012). Sources contributing to the average extracellular concentration of dopamine in the nucleus accumbens. J Neurochem 121:252-262.
133. Palmiter RD (2007). Is dopamine a physiologically relevant mediator of feeding behavior? Trends Neurosci 30:375-381.
134. Palmiter RD (2008). Dopamine signaling in the dorsal striatum is essential for motivated behaviors: lessons from dopamine-deficient mice. Ann NY Acad Sci 1129:35-46.
135. Panksepp J, Bishop P, Rossi J III (1979). Neurohumoral and endocrine control of feeding. Psychoneuroendocrinology 4:89-106.
136. Pederson KJ, Roerig JL, Mitchell JE (2003). Towards the pharmacotherapy of eating disorders. Expert Opin Pharmacother 4:1659-1678.
137. Pierce WD, Epling WF, Dews PB, Estes WK, Morse WH, Van Orman W, Herrnstein RJ (1994). Activity anorexia: an interplay between basic and applied behavior analysis. Behav Anal 17:7-23.
138. Pijnenburg AJ, Honig WM, Van der Heyden JA, Van Rossum JM (1976). Effects of chemical stimulation of the mesolimbic dopamine system upon locomotor activity. Eur J Pharmacol 35:45-58.
139. Pirke KM, Broocks A,Wilckens T, Marquard R, Schweiger U (1993). Starvationinduced hyperactivity in the rat: the role of endocrine and neurotransmitter changes. Neurosci Biobehav Rev 17:287-294.
140. Powers PS, Santana C (2004). Available pharmacological treatments for anorexia nervosa. Expert Opin Pharmacother 5:2287-2292.
141. Powers PS, Santana CA, Bannon YS (2002). Olanzapine in the treatment of anorexia nervosa: an open label trial. Int J Eat Disord 32:146-154.
142. Powers PS, Bannon Y, Eubanks R, McCormick T (2007). Quetiapine in anorexia nervosa patients: an open label outpatient pilot study. Int J Eat Disord 40: 21-26.
143. Rask-Andersen M, Olszewski PK, Levine AS, Schioth HB (2010). Molecular mechanisms underlying anorexia nervosa: focus on human gene association studies and systems controlling food intake. Brain Res Rev 62:147-164.
144. Rigaud D, Verges B, Colas-Linhart N, Petiet A, Moukkaddem M, VanWymelbeke V, Brondel L (2007). Hormonal and psychological factors linked to the increased thermic effect of food in malnourished fasting anorexia nervosa. J Clin Endocrinol Metab 92:1623-1629.
145. Roberts AC, De Salvia MA, Wilkinson LS, Collins P, Muir JL, Everitt BJ, Robbins TW (1994). 6-Hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analog of theWisconsin Card Sort Test: possible interactions with subcortical dopamine. J Neurosci 14 (5 Pt 1): 2531-2544.
146. Roberts ME, Tchanturia K, Stahl D, Southgate L, Treasure J (2007). A systematic review and meta-analysis of set-shifting ability in eating disorders. Psychol Med 37:1075-1084.
147. Rockwell WJ (1986). Pharmacological approaches to the treatment of eating disorders. New Dir Ment Health Serv 31:61-69.
148. Roesch-Ely D, Scheffel H, Weiland S, Schwaninger M, Hundemer HP, Kolter T, Weisbrod M (2005). Differential dopaminergic modulation of executive control in healthy subjects. Psychopharmacology (Berl) 178:420-430.
149. Rogers RD, Everitt BJ, Baldacchino A, Blackshaw AJ, Swainson R, Wynne K, et al. (1999). Dissociable deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depleted normal volunteers: evidence for monoaminergic mechanisms. Neuropsychopharmacology 20:322-339.
150. Routtenberg A, Kuznesof AW (1967). Self-starvation of rats living in activity wheels on a restricted feeding schedule. J Comp Physiol Psychol 64:414-421.
151. Ruggiero GM, Laini V, Mauri MC, Ferrari VM, Clemente A, Lugo F, et al. (2001). A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics. Prog Neuropsychopharmacol Biol Psychiatry 25:1049-1059.
152. Salamone JD, Correa M (2002). Motivational views of reinforcement: implications for understanding the behavioral functions of nucleus accumbens dopamine. Behav Brain Res 137:3-25.
153. Salamone JD, Mahan K, Rogers S (1993). Ventrolateral striatal dopamine depletions impair feeding and food handling in rats. Pharmacol Biochem Behav 44:605-610.
154. Scheurink AJ, Boersma GJ, Nergardh R, Sodersten P (2010). Neurobiology of hyperactivity and reward: agreeable restlessness in anorexia nervosa. Physiol Behav 100:490-495.
155. Schultz W (2007). Behavioral dopamine signals. Trends Neurosci 30:203-210.
156. Smith GP, Schneider LH (1988). Relationships between mesolimbic dopamine function and eating behavior. Ann NY Acad Sci 537:254-261.
157. Smith KS, Berridge KC, Aldridge JW (2011). Disentangling pleasure from incentive salience and learning signals in brain reward circuitry. Proc Natl Acad Sci USA 108:E255-E264.
158. Suematsu H, Kurokawa N, Tamai H, Ikemi Y (1974). Changes of serum growth hormone in psychosomatic disorders. Psychother Psychosom 24:161-164.
159. Tateno M, Teshirogi H, Kamasaki H, Saito T (2008). Successful olanzapine treatment of anorexia nervosa in a girl with pervasive developmental disorder not otherwise specified. Psychiatry Clin Neurosci 62:752.
160. Tidey JW, Miczek KA (1996). Social defeat stress selectively alters mesocorticolimbic dopamine release: an in vivo microdialysis study. Brain Res 721:140-149.
161. Ungerstedt U (1971). Stereotaxic mapping of the monoamine pathways in the rat brain. Acta Physiol Scand Suppl 367:1-48.
162. Van Binsbergen CJ, Odink J, Van der Beek EJ, Westenberg HM, Bennink HJ (1991). Biogenic amines in anorexia nervosa: circadian rhythm in urinary excretion and influence of posture and physical task load on plasma catecholamines. Psychosom Med 53:440-452.
163. Vandereycken W (1984). Neuroleptics in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled study with sulpiride. Br J Psychiatry 144:288-292.
164. Vandereycken W, Pierloot R (1982). Pimozide combined with behavior therapy in the short-term treatment of anorexia nervosa. A double-blind placebocontrolled cross-over study. Acta Psychiatr Scand 66:445-450.
165. Venugopalan VV, Casey KF, O'Hara C, O'Loughlin J, Benkelfat C, Fellows LK, Leyton M (2011). Acute phenylalanine/tyrosine depletion reduces motivation to smoke cigarettes across stages of addiction. Neuropsychopharmacology 36:2469-2476.
166. Verhagen LA, Luijendijk MC, Hillebrand JJ, Adan RA (2009a). Dopamine antagonism inhibits anorectic behavior in an animal model for anorexia nervosa. Eur Neuropsychopharmacol 19:153-160.
167. Verhagen LA, Luijendijk MC, Korte-Bouws GA, Korte SM, Adan RA (2009b). Dopamine and serotonin release in the nucleus accumbens during starvationinduced hyperactivity. Eur Neuropsychopharmacol 19:309-316.
168. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Gifford A, et al. (1999). Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels. Am J Psychiatry 156:1440-1443.
169. Volkow ND,Wang GJ, Fowler JS, Telang F (2008). Overlapping neuronal circuits in addiction and obesity: evidence of systems pathology. Philos Trans R Soc Lond B Biol Sci 363:3191-3200.
170. Vucetic Z, Reyes TM (2010). Central dopaminergic circuitry controlling food intake and reward: implications for the regulation of obesity. Wiley Interdiscip Rev Syst Biol Med 2:577-593.
171. Wachtel SR, Ortengren A, de Wit H (2002). The effects of acute haloperidol or risperidone on subjective responses to methamphetamine in healthy volunteers. Drug Alcohol Depend 68:23-33.
172. Wagner A, Aizenstein H, Venkatraman VK, Fudge J, May JC, Mazurkewicz L, et al. (2007). Altered reward processing in women recovered from anorexia nervosa. Am J Psychiatry 164:1842-1849.
173. Waldhauser F, Toifl K, Spona J, Zeitlhuber U, Waldhauser M, Frisch H (1984). Diminished prolactin response to thyrotropin and insulin in anorexia nervosa. J Clin Endocrinol Metab 59:538-541.
174. Wang TS, Chou YH, Shiah IS (2006). Combined treatment of olanzapine and mirtazapine in anorexia nervosa associated with major depression. Prog Neuropsychopharmacol Biol Psychiatry 30:306-309.
175. Wellman PJ (2005). Modulation of eating by central catecholamine systems. Curr Drug Targets 6:191-199.
176. Yasuhara D, Nakahara T, Harada T, Inui A (2007). Olanzapine-induced hyperglycemia in anorexia nervosa. Am J Psychiatry 164:528-529.
177. Zink CF, Weinberger DR (2010). Cracking the moody brain: the rewards of self starvation. Nat Med 16:1382-1383.